Results
1 -
10 of
119Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism, Cancer Chemotherapy and Pharmacology Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward, Psychopharmacology Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells, Journal of Neuro-Oncology Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy, Supportive Care in Cancer Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin, Supportive Care in Cancer Management of Nausea and Vomiting in Cancer Patients, Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting, Supportive Care in Cancer Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists, Supportive Care in Cancer